Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.60 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.60 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.60 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.60 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.60 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.60 |
| ▸ | GAA known ✓ | P10253 | 3/20 | 0.41 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6661600 | 0.99 | ADRA2A (0.61) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL10480272 | 0.97 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL9380029 | 0.88 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL9377803 | 0.88 | ADRA2A (0.57) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL9533878 | 0.88 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL9378433 | 0.88 | ADRA2A (0.57) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL9378974 | 0.87 | KDM4E (0.46) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL9376420 | 0.86 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL9378609 | 0.86 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL9376108 | 0.86 | ALDH1A1 (0.45) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0663014-B1 | DNA ENCODING HUMAN ALPHA 1 ADRENERGIC RECEPTORS AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2004-08-18 | — | — | EP | disclosed |
| US-6602888-B2 | Binds to a human alpha 1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human alpha 1A adrenergic receptor | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-08-05 | — | — | US | disclosed |
| US-20030113772-A1 | DNA encoding human alpha 1 adrenergic receptors and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-06-19 | — | — | US | disclosed |
| US-20030113771-A1 | DNA encoding human alpha 1 adrenergic receptors and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-06-19 | — | — | US | disclosed |
| US-20030022900-A1 | Compositions comprising alpha-1C specific compounds | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-01-30 | — | — | US | disclosed |
| US-6448011-B1 | ISOLATED NUCLEIC ACID, VECTORS, TRANSFORMED MAMMALIAN CELLS AND NON-HUMAN TRANSGENIC ANIMALS THAT ENCODE AND EXPRESS NORMAL OR MUTANT ADRENERGIC RECEPTOR GENES. | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-09-10 | — | — | US | disclosed |
| US-20020032219-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | H. LUNDBECK A/S (DK) | 2002-03-14 | — | — | US | disclosed |
| EP-1063291-A2 | DNA encoding human alpha 1 adrenergic receptors and uses thereof | Synaptic Pharmaceutical Corporation (US) | 2000-12-27 | — | — | EP | disclosed |
| EP-1063292-A2 | DNA encoding human alpha 1 adrenergic receptors and uses thereof | Synaptic Pharmaceutical Corporation (US) | 2000-12-27 | — | — | EP | disclosed |
| US-6156518-A | Methods of using DNA encoding human alpha 1 adrenergic receptors | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-12-05 | — | — | US | disclosed |
| WO-1994010989-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1994-05-26 | — | — | WO | disclosed |
| EP-0384677-B1 | Alpha-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1993-12-01 | — | — | EP | disclosed |
| US-5006521-A | α-adrenergic receptor antagonists and methods of use thereas | SMITHKLINE BEECHAM CORPORATION (US) | 1991-04-09 | — | — | US | disclosed |
| US-4981848-A | CARDIOVASCULAR, HYPOTENSIVE, ANTIDEPRESSANT | SMITHKLINE BEECHAM CORPORATION (US) | 1991-01-01 | — | — | US | disclosed |
| US-4963547-A | HYPOTENSIVE AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1990-10-16 | — | — | US | disclosed |
| EP-0384677-A1 | Alpha-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1990-08-29 | — | — | EP | disclosed |
| WO-1989012054-A1 | alpha-ADRENERGIC RECEPTOR ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-12-14 | — | — | WO | disclosed |
| WO-1989012053-A1 | alpha-ADRENERGIC RECEPTOR ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-12-14 | — | — | WO | disclosed |
| EP-0344981-A2 | Alpha-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-12-06 | — | — | EP | disclosed |
| EP-0344979-A2 | Alfa-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022900-A1 | Compositions comprising alpha-1C specific compounds | ADRB1, ADRA1B, ADRA1A | ADRA2A 9/4885ADRA2B 6/4885ADRA2C 8/4885 |
| US-20020032219-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | ADRB1, ADRA1B, ADRA1A | ADRA2A 9/4885ADRA2B 5/4885ADRA2C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.